First Gynecological Procedures Performed with Medtronic Hugo Robotic-Assisted Surgery System

- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first gynecological (GYN) procedures with the Hugo™ robotic-assisted surgery (RAS) system. The six cases included hysterectomies and myomectomies performed by Salomón Zebede, M.D., and Juan Carlos López, M.D., last week at Pacifica Salud Hospital in Panama City, Panama .

Salomón Zebede, M.D., a urogynecology and reconstructive pelvic surgeon and member of the robotic department at Pacifica Salud Hospital in Panama, gets ready to perform one of the first gynecologic procedures with the Hugo™ robotic-assisted surgery system.

"As the cornerstone of our new robotic surgery program, the Hugo RAS system is playing a critical role in bringing the benefits of minimally invasive surgery to more patients in our region," said Dr. Zebede. "It was energizing to perform the very first GYN procedure with the Hugo system, and encouraging to experience firsthand the possibility this technology brings to women's health."

Globally, more than 60% of hysterectomies are performed as open procedures, 1 even though minimally invasive surgery offers fewer complications, shorter hospital stays, and faster return to normal activities. 2-4

Pacifica Salud is the latest institution to join Medtronic's Partners in Possibility Program, a group of pioneering hospitals that will be among the first in the world to use the Hugo RAS system. Earlier this month, the hospital announced its first five urological cases with the Hugo RAS system. Pacifica Salud is also an early adopter of Touch Surgery™ Enterprise, a cloud-based surgical video capture solution that allows surgeons to seamlessly record, analyze, and share surgical video.

"We are witnessing the dawn of a new era in robotic surgery," said Mr. Rafael Cohen , CEO of Pacifica Salud. "That is made possible by the Hugo system, our partnership with Medtronic, and our talented team at Pacifica Salud."

The Hugo RAS system — Medtronic's solution to historic cost and utilization barriers that have kept surgical robotics out of reach for many hospitals — is a modular, multi-quadrant platform designed for a broad range of soft-tissue procedures. In June, Medtronic announced the first clinical procedures with the Hugo system took place in Santiago, Chile . That marked the beginning of the Hugo RAS system patient registry, which is collecting clinical data to support regulatory submissions around the world.

"As an OB/GYN, I'm incredibly passionate about advancing women's health and wellbeing through less invasive solutions that improve outcomes and enable a better quality of life," said Carla Peron , M.D., chief medical officer of the Surgical Robotics business, which is part of Medical Surgical Portfolio at Medtronic. "The first GYN procedures with the Hugo RAS system represent an exciting step toward expanding access to more treatment options, including the benefits of robotic-assisted surgery, to women everywhere."

Medtronic has a longstanding history of making a positive impact on women's health through technology. The Hugo RAS system joins a portfolio of gynecological products designed to enable less invasive surgical treatment of a range of conditions including abnormal uterine bleeding, uterine fibroids, and endometrial cancer.

"I'm proud of the work we're doing at Medtronic with our healthcare partners around the world to improve women's health," said Megan Rosengarten , president of Surgical Robotics. "Advancing access for women to minimally invasive surgical care is a great responsibility and privilege, which makes today's announcement about the Hugo system all the more meaningful."

The Hugo RAS system is not cleared or approved in the U.S. or Europe . Regulatory requirements of individual countries and regions will determine availability and approval or clearance timelines. Touch Surgery Enterprise is available in the U.S. and Europe ; it is not intended to direct surgery, or aid in diagnosis or treatment of a disease or condition.

For more information, visit medtronic.com/hugo .

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

  1. Based on internal estimates and Medtronic report, FY20 market model: procedural volume data.
  2. Fitch K, Engel T, Bochner A. Cost differences between open and minimally invasive surgery. Managed Care. 2015 Sep;24(9):40–8.
  3. Tiwari MM, Reynoso JF, High R, Tsang AW, Oleynikov D. Safety, efficacy, and cost effectiveness of common laparoscopic procedures. Surg Endosc. 2011;25(4):1127-1135.
  4. Roumm AR, Pizzi L, Goldfarb NI, Cohn H. Minimally invasive: minimally reimbursed? An examination of six laparoscopic surgical procedures. Surg Innovation. 2005;12(3):261–287.

Contacts:




Gary Jeanfaivre

Ryan Weispfenning

Public Relations

Investor Relations

+1-203-833-2104

+1-763-505-4626

Touch Surgery™ Enterprise is a cloud-based surgical video capture solution that allows surgeons to seamlessly record, analyze, and share surgical video.

The Hugo™ robotic-assisted surgery system from Medtronic is a modular, multi-quadrant platform for soft-tissue robotic-assisted surgery.

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/first-gynecological-procedures-performed-with-medtronic-hugo-robotic-assisted-surgery-system-301343980.html

SOURCE Medtronic plc

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/July2021/29/c5290.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

New clinical data demonstrate excellent lesion durability with PulseSelect Pulsed Field Ablation System in real-world setting as approvals and adoption expand globally

  • APHRS: New data confirm robust long-term durability and highly efficient procedure performed without fluoroscopy
  • Successful launch in Japan follows recent reimbursement approval
  • Approvals across APAC including China and Australia broaden reach for patients

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect™ Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstrated durable isolation in 98% of pulmonary veins (PV) and 96% of patients had all veins isolated.

Results were presented as a late breaking clinical trial at the Asia Pacific Heart Rhythm Society (APHRS) meeting in Sydney, Australia .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or "the Company") is pleased to announce it has ranked No. 397 on the 2024 Report on Business magazine's ranking of Canada's Top Growing Companies.

Canada's Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 64%.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic expands AiBLE spine surgery ecosystem with new technologies and Siemens Healthineers partnership

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today at the North American Spine Society (NASS) 39 th Annual Meeting in Chicago the commercial launch of several software, hardware, and imaging innovations. These enhancements are designed to advance AiBLE™, the Medtronic smart ecosystem of innovative navigation, robotics, data and AI, imaging, software and implants that enable more predictable outcomes in spine and cranial procedures. In line with its commitment to increasing the quality of care for patients with spinal conditions, Medtronic also announced a partnership with Siemens Healthineers to explore opportunities to further expand access to advanced pre- and post-operative imaging technologies for spine care.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Surgeons stand around a hospital bed with patient on it and a surgical robot above it.

8 Surgical Robotics Stocks (Updated 2024)

Robotics technology is quickly disrupting a variety of sectors, including the medical space, and surgical robot applications are a major component of the overall medical robots market.

In fact, a Grand View Research report projects that this industry will reach a value of US$7.42 billion by 2030, up from an estimated US$4.31 billion in 2024. According to the firm, the increased need for procedure-specific surgical robots and advancements in medical robot technology are seen as the main drivers of this sector.

Surgical robotics companies are developing products for a variety of surgery types, including cardiac, spinal and endoluminal surgeries. The tools these firms provide can increase surgeons’ performance ability and can lessen scarring, incisions, blood loss and more. They can also make surgeries safer and lead to a more comfortable recovery.

Keep reading...Show less

Thermo Fisher Scientific Hosts 2024 Investor Day

Highlights Include the Company's Industry-Leading Businesses, Proven Growth Strategy, and Outstanding Long-Term Financial Outlook

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

Cleo Commences U.S. Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test.

Keep reading...Show less

Latest Press Releases

Related News

×